Gamage Manoji, Ranawaka Randula
Nutrition Division, Ministry of Health, Colombo 0094, Sri Lanka.
Medical Nutrition Unit, National Institute of Nephrology, Dialysis and Transplant, Colombo 0094, Sri Lanka.
World J Transplant. 2024 Dec 18;14(4):95967. doi: 10.5500/wjt.v14.i4.95967.
Growth retardation is a significant complication observed in pediatric renal transplant recipients, originating from a multifactorial etiology. Factors contributing to growth impairment encompass pre-transplant conditions such as primary kidney disease, malnutrition, quality of care, growth deficits at the time of transplantation, dialysis adequacy, and the use of recombinant human growth hormone. Additionally, elements related to the renal transplant itself, such as living donors, corticosteroid usage, and graft functioning, further compound the challenge. Although renal transplantation is the preferred renal replacement therapy, its impact on achieving final height and normal growth in children remains uncertain. The consequences of growth delay extend beyond the physiological realm, negatively influencing the quality of life and social conditions of pediatric renal transplant recipients, and ultimately affecting their educational and employment outcomes. Despite advancements in graft survival rates, growth retardation remains a formidable clinical concern among children undergoing renal transplantation. Major risk factors for delayed final adult height include young age at transplantation, pre-existing short stature, and the use of specific immunosuppressive drugs, particularly steroids. Effective management of growth retardation necessitates early intervention, commencing even before transplantation. Strategies involving the administration of recombinant growth hormone both pre- and post-transplant, along with protocols aimed at minimizing steroid usage, are important for achieving catch-up growth. This review provides a comprehensive outline of the multifaceted nature of growth retardation in pediatric renal transplant recipients, emphasizing the importance of early and targeted interventions to mitigate its impact on the long-term well-being of these children from birth to adolescence.
生长迟缓是小儿肾移植受者中观察到的一种重要并发症,其病因是多因素的。导致生长受损的因素包括移植前的状况,如原发性肾病、营养不良、护理质量、移植时的生长缺陷、透析充分性以及重组人生长激素的使用。此外,与肾移植本身相关的因素,如活体供体、皮质类固醇的使用和移植物功能,进一步加剧了这一挑战。尽管肾移植是首选的肾脏替代疗法,但其对儿童最终身高和正常生长的影响仍不确定。生长延迟的后果超出了生理范畴,对小儿肾移植受者的生活质量和社会状况产生负面影响,并最终影响他们的教育和就业结果。尽管移植物存活率有所提高,但生长迟缓仍然是接受肾移植儿童中一个严峻的临床问题。最终成人身高延迟的主要风险因素包括移植时年龄小、既往身材矮小以及使用特定的免疫抑制药物,尤其是类固醇。有效管理生长迟缓需要早期干预,甚至在移植前就开始。移植前后给予重组生长激素的策略,以及旨在尽量减少类固醇使用的方案,对于实现追赶生长很重要。本综述全面概述了小儿肾移植受者生长迟缓的多方面性质,强调早期和有针对性干预对于减轻其对这些儿童从出生到青春期长期健康影响的重要性。